Skip to main navigation

English
Français

IR Navigation

Overview
News
Events & Presentations
- Events
- Presentations
Stock Information
Financials
Governance
Resources

Press Releases

Press Releases

Year

17 Dec 2021

On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset

17 Dec 2021

GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership

18 Nov 2021

GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology’s Unique Performance in Identifying Patients with “at-risk” NASH

09 Nov 2021

GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of its ACLF Program

08 Nov 2021

GENFIT: Third Quarter 2021 Financial Information

02 Nov 2021

New Clinical Data on GENFIT’s Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting®

29 Sep 2021

GENFIT Reports First Half-Year 2021 Financial Results and Provides Corporate Update

09 Jul 2021

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

30 Jun 2021

GENFIT: June 30, 2021 Annual Shareholders Meeting results

24 Jun 2021

GENFIT obtains non-dilutive financing of €11 million in the form of a State Guaranteed Loan

23 Jun 2021

GENFIT presents new NIS4® data in NASH at the International Liver Congress™ and the 81st Scientific Sessions of the American Diabetes Association

15 Jun 2021

GENFIT: June 15, 2021 Combined Shareholders Meeting: Wide support for the resolutions submitted to the shareholders’ vote but quorum not met on first convening

27 May 2021

GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021

12 May 2021

GENFIT: Reports First Quarter 2021 Financial Information

11 May 2021

GENFIT Provides Pipeline Update and Launch of New Clinical Programs

10 May 2021

GENFIT Annual Combined General Meeting of June 15, 2021 - Availability of Preparatory Documents

03 May 2021

GENFIT announces the launch by Labcorp of NASHnext® A Novel Noninvasive Diagnostic Test Powered by GENFIT’s NIS4™ Technology to Identify Patients with At-Risk NASH

23 Apr 2021

GENFIT: Publication of the 2020 Universal Registration Document and the 2020 Annual Report on Form 20-F; Annual Shareholders Meeting to take place on June 15, 2021

22 Apr 2021

GENFIT hires Thomas Baetz as Chief Financial Officer and adds two new members to its Executive Committee

01 Apr 2021

GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate Update

04 Mar 2021

GENFIT appoints Jean-François Tiné to the Board of Directors

26 Feb 2021

GENFIT: Revenues and Cash Position as of December 31, 2020

22 Feb 2021

GENFIT: new market research data highlight potential of elafibranor in PBC

10 Feb 2021

GENFIT: 2021 Financial Calendar

09 Feb 2021

GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology

28 Jan 2021

GENFIT Announces Two Key Appointments to the Executive Committee

27 Jan 2021

GENFIT: Technical Corrections to the Results of the January 25, 2021 Bondholders Meeting with No Impact on Resolutions’ Approval

25 Jan 2021

GENFIT: Sweeping approval of OCEANEs buyback and amendments of terms

13 Jan 2021

GENFIT announces that its Extraordinary General Meeting on second notice will be held January 25, 2021 and informs the OCEANEs holders of certain procedures for the Bondholders’ Meeting of January 25, 2021

12 Jan 2021

January 13, 2021 Extraordinary Shareholders Meeting: Wide support for the resolutions submitted to the shareholders’ vote but quorum not met on first convening

11 Jan 2021

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

08 Jan 2021

GENFIT Informs its Shareholders of Certain Procedures for the Extraordinary General Meeting of January 13, 2021

06 Jan 2021

GENFIT to Present at Upcoming Investor Conferences and Host a PBC KOL Event

Shareholder Tools

Print Page
Email Alerts
RSS
Contact IR

Request E-mail Alerts

GENFIT Headquarters
Parc Eurasanté 885, Avenue Eugène Avinée 59120 Loos France GENFIT Corp
1 Alewife Center Suite 220 Cambridge MA 02140 USA

All rights reserved.